
ELVN Stock Forecast & Price Target
ELVN Analyst Ratings
Bulls say
Enliven Therapeutics Inc demonstrates a strong commitment to financial prudence by executing a workforce reduction and reallocating resources to focus on the promising development of HER3-targeting antibody-drug conjugate EO-1022. This strategic pivot aims to enhance the company's potential for revenue generation starting in 2031, as indicated by recent adjustments in their financial model, which prioritize key product candidates. Furthermore, addressing the challenges present in the biotechnology sector reinforces management's proactive approach to managing expenses and optimizing their developmental roadmap, positioning the company favorably for future growth opportunities.
Bears say
Enliven Therapeutics has faced significant setbacks with its development pipeline, notably the decision to discontinue the Claudin 18.2-targeting ADC, EO-3021, due to lower-than-expected efficacy observed in its Phase 1 study, despite the drug's tolerability. The failure to achieve robust efficacy in this candidate raises concerns about the potential for future product development and the company's overall financial health. Furthermore, the downward adjustment of the price target from $6.00 to $1.00 reflects diminished investor confidence in the company’s prospects and future growth potential.
This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ELVN Analyst Forecast & Price Prediction
Start investing in ELVN
Order type
Buy in
Order amount
Est. shares
0 shares